Abbott Laboratories (ABT): Price and Financial Metrics
Abbott Laboratories (ABT)
Today's Latest Price: $107.99 USD
Updated Sep 30 3:31pm
Add ABT to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 239 in Medical - Pharmaceuticals
See all "A" rated Strong Buy stocks
ABT Stock Summary
- Abbott Laboratories's market capitalization of $186,242,050,595 is ahead of 99.19% of US-listed equities.
- Abbott Laboratories's stock had its IPO on January 1, 1986, making it an older stock than 92.91% of US equities in our set.
- The volatility of Abbott Laboratories's share price is greater than that of only 7.81% US stocks with at least 200 days of trading history.
- If you're looking for stocks that are quantitatively similar to Abbott Laboratories, a group of peers worth examining would be SAP, SHOP, CCI, CMCSA, and PEP.
- Visit ABT's SEC page to see the company's official filings. To visit the company's web site, go to www.abbott.com.
ABT Stock Price Chart Technical Analysis Charts
ABT Price/Volume Stats
| Current price | $107.99 | 52-week high | $114.19 |
| Prev. close | $105.19 | 52-week low | $61.61 |
| Day low | $105.74 | Volume | 5,895,168 |
| Day high | $109.48 | Avg. volume | 7,337,938 |
| 50-day MA | $103.32 | Dividend yield | 1.37% |
| 200-day MA | $91.58 | Market Cap | 191.20B |
Abbott Laboratories (ABT) Company Bio
Abbott Laboratories manufactures and sells health care products worldwide. The company operates in four business segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Vascular Products. The company was founded in 1888 and is based in Abbott Park, Illinois.
ABT Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $107.99 | $36.2 | -66% |
Below please find a table outlining a discounted cash flow forecast for ABT, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Abbott Laboratories ranked in the 21th percentile in terms of potential gain offered. Our DCF analysis suggests the stock is overvalued by about 65.5%. The most interesting components of our discounted cash flow analysis for Abbott Laboratories ended up being:
- As a business, ABT is generating more cash flow than 90.99% of positive cash flow stocks in the Healthcare.
- The business' balance sheet reveals debt to be 9% of the company's capital (with equity being the remaining amount). Approximately merely 21.78% of US stocks with free cash flow have a lower reliance on debt in their capital structure.
- ABT's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 2%; for context, that number is higher than 38.4% of tickers in our DCF set.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | -66% |
| 1% | -66% |
| 2% | -66% |
| 3% | -65% |
| 4% | -65% |
| 5% | -65% |
For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as ABT, try BAX, BIO, OFIX, REPH, and SRDX.
Loading social stream, please wait...